A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed With Schizophrenia
Latest Information Update: 16 Jun 2022
At a glance
- Drugs Asenapine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Noven Pharmaceuticals
- 06 Jun 2022 The Post hoc analysis assessing specific effect of the HP-3070 asenapine transdermal system on the symptoms of hostility and agitation in adults with schizophrenia published in the Journal of Clinical Psychiatry.
- 15 Dec 2020 Results published in the Journal of Clinical Psychiatry
- 15 Oct 2019 According to a Noven Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved SECUADO (asenapine) transdermal system for the treatment of adults with schizophrenia.